title: Clinical use of abiraterone in the treatment of metastatic castration-resistant prostate cancer.
abstract: Prostate cancer remains the most common type of cancer among men in the United States. Treatment for metastatic prostate cancer has improved significantly over the years with more and more agents improving overall survival. This review will address the pathophysiology of prostate cancer followed by the mechanism of action and the pharmacokinetic properties of abiraterone. The review will also discuss the role of abiraterone in the treatment of metastatic castrate-resistant prostate cancer.
authors.affiliation: Department of Pharmacy, Roswell Park Cancer Institute, Buffalo, NY, USA.
authors.forename: Chrystia M
authors.initials: CM
authors.lastname: Zobniw
authors.affiliation: School of Pharmacy, Lake Erie College of Osteopathic Medicine, Erie, PA, USA.
authors.forename: Alanna
authors.initials: A
authors.lastname: Causebrook
authors.affiliation: Department of Pharmacy, Roswell Park Cancer Institute, Buffalo, NY, USA.
authors.forename: Mei Ka
authors.initials: MK
authors.lastname: Fong
keywords: CYP17; drug resistance; enzalutamide; glucocorticoid receptor; pipeline; radium-223 dichloride; sipuleucel-T